盐酸氨溴索辅助治疗慢性支气管炎的药效评价

目的探讨盐酸氨溴索辅助治疗慢性支气管炎的药用价值。方法将本院诊治的80例慢性支气管炎患者随机分成两组:对照组40例,单纯采用阿莫西林治疗;实验组40例,采用盐酸氨溴索+阿莫西林治疗。观察与比较两组的临床疗效、症状积分、肺功能、血气分析。结果实验组的总有效率显著性高于对照组(P<0.05);实验组患者治疗后的气喘、咳嗽、咳痰等症状积分均显著性低于对照组(P<0.05);实验组患者治疗后的FEV1、FEV1%等肺功能指标水平均显著性高于对照组(P<0.05);实验组患者治疗后的PaO2、PaCO2等血气分析值显著性优于对照组(P<0.05)。结论临床应用盐酸氨溴索治疗慢性支气管炎能显著改善临床症状和肺功能水平。     

氨溴索联合抗菌药物治疗老年糖尿病合并肺炎的疗效

目的 探讨老年糖尿病合并肺炎应用氨溴索联合抗菌药物治疗的临床疗效及成本-效果分析.方法 采用氨溴索联合头孢哌酮钠舒巴坦钠联合治疗老年糖尿病合并肺炎患者,并与盐酸溴己新片联合头孢哌酮钠舒巴坦钠治疗的对照组进行临床疗效、症状、成本-效果及不良反应比较.结果 观察组的痊愈率和总有效率均明显高于对照组(P<0.05);观察组发热、咳嗽咯痰等症状较治疗前明显改善,且与对照组治疗后比较有明显差异(P<0.05);观察组发热、咳嗽咯痰等症状的改善起效时间较对照组明显缩短(P<0.05),平均住院天数明显较对照组缩短(P<0.05).从成本-效果比上分析,发现观察组的用药更经济实用.治疗过程中两组均未出现明显不良反应.结论 氨溴索联合头孢哌酮钠舒巴坦钠治疗老年糖尿病合并肺炎的疗效确切,成本-效果较佳,且安全性也较佳,值得临床推广应用.     

氨溴索联合多索茶碱治疗慢性支气管炎急性发作临床分析

目的探讨分析氨溴索联合多索茶碱治疗慢性支气管炎急性发作的临床疗效。方法将86例慢性支气管炎急性发作患者随机分为观察组和对照组,每组43例。观察组患者给予氨溴索联合多索茶碱治疗,对照组患者只给予氨溴索治疗,观察比较两组患者咳嗽、咳痰、湿啰音等症状消失时间、住院时间以及临床治疗效果。结果观察组患者治疗总有效率(93.02%)显著高于对照组患者(74.42%),差异具有统计学意义(P0.05),观察组患者临床疗效优于对照组患者(P0.01)。观察组患者的咳嗽、咳痰、肺部湿啰音等症状消失时间和住院时间均显著短于对照组患者,差异具有统计学意义(P0.05)。治疗后观察组患者的喘息、咳痰、咳嗽等症状评分均低于对照组患者,差异具有统计学意义(P0.05)。两组患者均无严重不良反应发生。结论盐氨溴索联合多索茶碱治疗慢性支气管炎急性发作临床疗效显著,不良反应轻微,具有推广应用价值。     

盐酸氨溴索雾化吸入法治疗老年慢性支气管炎的疗效分析

目的探讨盐酸氨溴索雾化吸入法治疗老年慢性支气管炎的疗效。方法选取2012年2年~2015年2月我院收治的老年慢性支气管患者60例作为研究对象,将其分为观察组和对照组,各30例。对照组患者采用常规药物雾化吸入法进行病情治疗,观察组患者采用盐酸氨溴索雾化吸入法进行病情治疗,最后比较两组患者使用不同治疗方法后的疗效。结果观察组老年慢性支气管炎患者的疗效优于对照组,差异有统计学意义(P0.05)。结论对于老年慢性支气管炎患者的治疗,采用盐酸氨溴索雾化吸入法进行治疗,能有效地改善患者老年慢性支气管的症状,并且具有疗效快速、治疗方便的临床特点。     

盐酸氨溴索注射液治疗老年慢性支气管炎急性发作的临床疗效

目的观察盐酸氨溴索注射液治疗老年慢性支气管炎急性发作的临床疗效。方法选取2015年11月—2016年11月海南省第二人民医院收治的老年慢性支气管炎急性发作患者86例,随机分为对照组和观察组,每组43例。对照组患者给予常规治疗,而观察组患者在常规治疗基础上给予盐酸氨溴索注射液治疗;两组患者均连续治疗2周。比较两组患者临床疗效、治疗前后肺功能指标[包括第1秒用力呼气容积(FEV_1)、用力肺活量(FVC)、FEV_1/FVC]及不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者FEV_1、FVC、FEV_1/FVC比较,差异无统计学意义(P>0.05);治疗后观察组患者FEV_1、FVC、FEV_1/FVC高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论盐酸氨溴索注射液治疗老年慢性支气管炎急性发作的临床疗效确切,可有效改善患者肺功能且安全性较高。     

盐酸氨溴索治疗慢性支气管炎的疗效分析

目的探讨盐酸氨溴索治疗慢性支气管炎的疗效。方法选取2012年12月~2014年12月我院收治的慢性支气管炎患者82例作为研究对象,按照随机原则将其分为研究组与对照组,各41例。两组患者均采取常规治疗,对照组患者进行必嗽平注射液治疗,研究组患者进行盐酸氨溴索治疗,分析两组患者的疗效。结果研究组患者总有效率明显高于对照组,差异有统计学意义(P0.05)。结论对慢性支气管炎患者给予盐酸氨溴索治疗的疗效较好,可有效改善患者的临床症状,值得临床推广应用。     

盐酸氨溴索治疗慢性支气管炎患者临床疗效观察

目的探讨盐酸氨溴索治疗慢性支气管炎患者的临床疗效。方法选取慢性支气管炎患者184例作为研究对象,随机分为对照组和观察组,每组92例。对照组患者均给予左氧氟沙星或阿奇霉素治疗,重度患者给予多索茶碱与低流量吸氧治疗。观察组在对照组患者治疗的基础上给予盐酸氨溴索治疗。比较两组患者的临床治疗效果。结果两组患者治疗后第1天、第7天、第14天临床症状积分均显著降低(P0.05);观察组患者症状积分低于对照组(P0.05或0.01)。治疗7 d、14 d后,观察组患者WBC计数显著降低(P0.05),而对照组患者无显著变化;观察组患者WBC计数显著低于对照组(P0.05)。观察组患者治疗总有效率(89.1%)显著高于对照组(75.0%),差异有统计学意义(P0.05);观察组临床疗效优于对照组(P0.01)。结论在常规治疗基础上,联合盐酸氨溴索治疗慢性支气管炎患者疗效显著。     

盐酸氨溴索治疗慢性支气管炎的临床疗效观察

目的探讨盐酸氨溴索治疗慢性支气管炎(CB)的临床疗效。方法选取慢性支气管炎患者184例作为研究对象,采用随机数字表法随机分为对照组和观察组,每组92例。两组患者均给予左氧氟沙星或阿奇霉素治疗,病程严重者给予多索茶碱与低流量吸氧治疗,观察组患者在此基础上给予盐酸氨溴索治疗。评价比较两组患者的症状积分、白细胞计数、临床疗效。结果治疗后第1天、第7天、第14天,两组患者症状积分均显著降低(P0.05),观察组患者症状积分显著低于对照组(P0.05)。治疗7 d、14 d后,观察组患者WBC计数显著降低(P0.05),对照组无明显变化(P0.05),观察组患者WBC计数显著低于对照组(P0.05)。观察组患者治疗总有效率(89.1%)显著高于对照组(75.0%),观察组患者疗效优于对照组(P0.01)。结论在常规治疗基础上,联合盐酸氨溴索治疗CB患者,可有效控制患者感染和炎症反应,提高疗效。     

盐酸氨溴索治疗慢性支气管炎50例疗效观察

目的观察盐酸氨溴索治疗慢性支气管炎的疗效及安全性。方法选取慢性支气管炎患者100例,使用抛硬币方法随机分为观察组和对照组,各50例,对照组给予抗感染、吸痰、吸氧及止咳化痰等常规治疗,观察组在常规治疗的基础上加用盐酸氨溴索注射液进行治疗,2周后对两组患者的临床疗效进行对比分析。结果观察组患者治疗总有效率为94.0%,高于对照组(72.0%),两组比较差异有统计学意义(P0.05);两组患者均未观察到严重的药物不良反应,耐受性较好,均能按疗程完成治疗。结论盐酸氨溴索治疗慢性支气管炎疗效切确,不良反应少,安全性高,可在基层医疗单位中推广应用。     

沙丁胺醇联合氨溴索雾化吸入治疗支气管扩张症的疗效观察

目的观察沙丁胺醇联合氨溴索雾化吸入治疗支气管扩张症的临床疗效。方法 65例支气管扩张症患者随机分成两组,对照组(n=33)采用对症支持及抗感染治疗,观察组(n=32)在对照组治疗基础上加用沙丁胺醇联合氨溴索雾化吸入治疗。观察和比较两组患者治疗前后临床症状和肺功能改善情况。结果观察组临床症状缓解时间较对照组明显缩短(P<0.05);两组患者治疗后较治疗前肺功能均明显改善,且观察组改善更为明显(P<0.05)。结论沙丁胺醇联合氨溴索雾化吸入治疗支气管扩张症疗效显著,能明显改善患者的临床症状及肺功能。     

Mental disorders in patients with obesity in comparison with healthy probands

OBJECTIVE: Findings concerning the association of obesity and mental disorders are inconsistent. The present epidemiological study investigates adjusted 4-week, 12-month, and lifetime prevalence rates of mental disorders in obese individuals compared with physically healthy probands and overweight individuals. Correlates of the associations are examined. METHODS: Prevalence rates were calculated from two large epidemiological surveys from both the general population of Germany and inpatient centers. The surveys investigated subjects with obesity (n=910) and overweight (n=1550), as well as physically healthy probands (n=495). The prevalence rates were based on the Munich-composite international diagnostic interview, a standardized interview for the assessment of mental disorders. Correlates of mental disorders in obese individuals were assessed using self-report questionnaires and medical examinations. RESULTS: The adjusted odds ratios (OR) of obese inpatients and obese patients from the general population were significantly elevated in comparison with healthy probands for the 4-week (OR: 2.2; 2.3), 12-month (OR: 1.8; 2.7) and lifetime (OR: 1.4; 2.0) periods. Prevalence rates of overweight individuals were below those of obese individuals. Mood, anxiety and somatoform disorders were most frequent. In particular, sex, marital status and comorbid musculoskeletal diseases proved to be correlates of an increased risk for mental disorders in obese individuals. The presence of comorbid mental disorders was associated with significantly increased health care use and lower quality of life. CONCLUSIONS: There is a strong relationship between obesity and mental disorders. A future task is to improve care of mental disorders in patients with obesity.     

Changes in coagulation parameters with exercise in patients with classic hemophilia

Vigorous exercise is known to increase VIII:C and VIIIR:Ag levels transiently in normal individuals. Although exercise programs are frequently advocated in the management of hemophilia, the effects of exercise on coagulation parameters in these patients have not been well studied. Eleven hemophiliacs were exercised on a bicycle ergometer to maximum voluntary effort as evidenced by an increase in pulse, blood pressure, and plasma catecholamine (norepinephrine and epinephrine) levels. The effects of this exercise on coagulation parameters, including functional and antigenic components of the factor VIII molecule, were determined. The entire group demonstrated a decrease in mean prothrombin time (11.7 to 11.2 sec). Four mild hemophiliacs demonstrated an increase in mean VIII:C (14.5% to 17.3%), and VIII:CAg (12% to 17.8%). Changes in VIII:C and VIII:CAg were not noted in the seven severe hemophiliacs. Both severe and mild patients demonstrated significant changes in fibrinogen, factor II, and factor VII after exercise. This study indicates that submaximal exercise modifies coagulation parameters in patients with hemophilia.     

Therapy with budesonide in patients with refractory sprue

INTRODUCTION: Refractory sprue (RS) is a rare malabsorption syndrome, which often requires long-term corticosteroid treatment. Locally acting budesonide could replace systemic corticosteroid therapy and reduce toxicity in patients with RS. Aims: To evaluate the efficacy and toxicity of budesonide in patients with RS. PATIENTS AND METHODS: Clinical and histological data from patients with RS who received budesonide were analyzed. RS was defined as villous atrophy and malabsorption in spite of a strict gluten-free diet persisting for >6 months or requiring earlier therapeutic intervention. RESULTS: We identified 9 patients (1 with autoimmune enteropathy, 4 with RS type I without and 3 with RS type II with signs of early T cell lymphoma and 1 with CD4-positive sprue-like intestinal T cell lymphoma), who received 9 mg/day of budesonide (range 6-12) for 24 months (1-60), and 7 of whom had an initial treatment with 40 mg/day of prednisolone (30-60) for 4 months (1-144). The initial body mass index was 18 (13.1-22.8) and increased similarly under prednisolone [21.5 (14.9-26.7), p < 0.05] and budesonide therapy [21 (18-27.2), p < 0.05]. The stool frequency per day also decreased similarly from 6 (2-8) to 2 (1-3) and 2 (1-5), each p < 0.05, under prednisolone and budesonide therapy, respectively. Two patients with RS type II did not respond and 7, including all 4 with RS type I, were clinically stable with budesonide therapy. Skin fragility in 1 patient was the only adverse effect of budesonide therapy. CONCLUSIONS: Budesonide may be an effective treatment option in patients with RS type I, which can stabilize the clinical condition similar to prednisolone.     

Gammagraphy with sucralfate labelled with technetium in esophagitis

In previous studies it has been reported that, after being labeled with technetium, sucralfate, an useful drug in peptic diseases, can be used to detect peptic lesions of the digestive tract. In this work we report our experience with this technique in the diagnosis of esophagitis. 25 studies (11 controls and 14 patients) were undertaken. Sucralfate scintigraphy was normal in the 11 control studies, and abnormal in 10 out of 14 patients. Scintigraphy was abnormal in peptic as well as caustic lesions.     

Polymyositis-like syndrome with rhabdomyolysis in association with brucellosis

Diffuse myositis with progression to rhabdomyolysis has been reported in association with wide range of viral infections. We report a case of polymyositis-like syndrome complicated by rhabdomyolysis secondary to brucellosis. This case report thus contributes yet another atypical presentation to a disease already infamous for its protean manifestations.     

Metabolic remission with octreotide in patients with insulinoma

Abstract. Objectives . The efficacy of octreotide was studied in a group of patients with biochemical evidence of insulinoma. Design . A phase-II study Setting . A university department of internal medicine. Subjects . Seven patients with biochemical evidence of insulinoma and without metastatic lesions. Intervention . Daily treatment with octreotide, a somatostatin analogue, mainly within the dosage of 100–300 μg day^-1. The treatment was continued in patients with biochemical evidence of response or until surgery was undertaken. Main outcome . Five patients avoided hypoglycaemic symptoms and had normalization of blood glucose values for a median of 15+ months (range 0.2–54 months). Two did not improve metabolically. The treatment was well tolerated and had no deleterious effects on blood glucose regulation. Conclusion . Octreotide seems to be a promising treatment for many of the patients with insulinoma who are not suitable for surgery.